1. Home
  2. ONCT

ONCT

Oncternal Therapeutics Inc.

Logo Oncternal Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

Founded: N/A Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 25.6M IPO Year: N/A
Target Price: $32.00 AVG Volume (30 days): 11.0K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -13.43 EPS Growth: N/A
52 Week Low/High: $5.57 - $13.20 Next Earning Date: 05-02-2024
Revenue: $785,000 Revenue Growth: -47.32%
Revenue Growth (this year): -61.02% Revenue Growth (next year): 100.00%

Share on Social Networks: